Literature DB >> 30980099

Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies.

Seok Jong Chung1,2, Yang Hyun Lee1, Han Soo Yoo1, Young H Sohn1, Byoung Seok Ye1, Jungho Cha3, Phil Hyu Lee4,5.   

Abstract

PURPOSE: Little is known regarding the clinical relevance or neurobiology of subtle motor disturbance in Alzheimer's disease (AD). This study aims to investigate the patterns of striatal 18F-FP-CIT uptake in patients with AD-related cognitive impairment (ADCI) with mild parkinsonism.
METHODS: We recruited 29 consecutive patients with ADCI with mild parkinsonism. All patients underwent 18F-FP-CIT PET scans and dopamine transporter (DAT) availability in striatal subregions (anterior/posterior caudate, anterior/posterior putamen, ventral putamen, ventral striatum) was quantified. Additionally, 32 patients with dementia with Lewy bodies (DLB) and 21 healthy controls were included to perform inter-group comparative analyses of the striatal DAT availability. The discriminatory power of striatal DAT availability to differentiate ADCI from DLB was assessed using receiver operating characteristics (ROC) analyses. The Spearman's correlation coefficient was calculated to assess the relationship between motor severity and DAT availability in striatal subregions.
RESULTS: Patients with ADCI with mild parkinsonism exhibited decreased DAT availability in the caudate that was intermediate between healthy controls and patients with DLB. The DAT availability in other striatal subregions, including the posterior putamen, did not differ between the ADCI with parkinsonism and healthy control groups. The ROC analysis showed that DAT availability of all striatal subregions, especially the whole striatum, had a fair discriminatory power. Parkinsonian motor severity did not correlate with the striatal DAT availability in ADCI with parkinsonism.
CONCLUSIONS: The present study demonstrated that patients with ADCI with mild parkinsonism had distinct DAT scan patterns and suggests that parkinsonism is associated with the extranigral source of pathology.

Entities:  

Keywords:  Alzheimer’s disease; Dementia with Lewy bodies; Dopamine transporter; Parkinsonism

Mesh:

Substances:

Year:  2019        PMID: 30980099     DOI: 10.1007/s00259-019-04315-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  48 in total

1.  Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  Acta Neuropathol       Date:  2006-06-28       Impact factor: 17.088

Review 2.  The role of radiotracer imaging in Parkinson disease.

Authors:  B Ravina; D Eidelberg; J E Ahlskog; R L Albin; D J Brooks; M Carbon; V Dhawan; A Feigin; S Fahn; M Guttman; K Gwinn-Hardy; H McFarland; R Innis; R G Katz; K Kieburtz; S J Kish; N Lange; J W Langston; K Marek; L Morin; C Moy; D Murphy; W H Oertel; G Oliver; Y Palesch; W Powers; J Seibyl; K D Sethi; C W Shults; P Sheehy; A J Stoessl; R Holloway
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

3.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

4.  The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs.

Authors:  J M Burns; J E Galvin; C M Roe; J C Morris; D W McKeel
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

5.  Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study.

Authors:  D S Wolf; M Gearing; D A Snowdon; H Mori; W R Markesbery; S S Mirra
Journal:  Alzheimer Dis Assoc Disord       Date:  1999 Oct-Dec       Impact factor: 2.703

6.  Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study.

Authors:  R Ceravolo; D Volterrani; G Gambaccini; S Bernardini; C Rossi; C Logi; G Tognoni; G Manca; G Mariani; U Bonuccelli; L Murri
Journal:  J Neural Transm (Vienna)       Date:  2004-06-18       Impact factor: 3.575

7.  Motor signs during the course of Alzheimer disease.

Authors:  N Scarmeas; G M Hadjigeorgiou; A Papadimitriou; B Dubois; M Sarazin; J Brandt; M Albert; K Marder; K Bell; L S Honig; D Wegesin; Y Stern
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

8.  MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease.

Authors:  Osvaldo P Almeida; Emma J Burton; Ian McKeith; Anil Gholkar; David Burn; John T O'Brien
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

9.  Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.

Authors:  Z Walker; D C Costa; R W H Walker; L Lee; G Livingston; E Jaros; R Perry; I McKeith; C L E Katona
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

10.  Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

Authors:  John T O'Brien; Sean Colloby; John Fenwick; E David Williams; Michael Firbank; David Burn; Dag Aarsland; Ian G McKeith
Journal:  Arch Neurol       Date:  2004-06
View more
  1 in total

1.  Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts.

Authors:  Melissa J Armstrong; David J Irwin; James B Leverenz; Noheli Gamez; Angela Taylor; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.